Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elisa Andrini
Observed names:
Andrini, Elisa,
E. Andrini
Institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
Observed institutions:
Vita-Salute San Raffaele University,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma,
University of Bologna
ORCID:
0000-0003-2952-1507
Observed ORCID:
0000-0003-2952-1507
OpenAlex ID:
A5076045697
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020
·
Giuseppe Lamberti
, Elisa Andrini
, et al.
·
Critical Reviews in Oncology/Hematology
·
152
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges
2022
·
Elisa Andrini
, Paola Valeria Marchese
, et al.
·
Journal of Clinical Medicine
·
89
PDF
Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
2021
·
Veronica Mollica
, Alessandro Rizzo
, et al.
·
Cancers
·
72
PDF
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
2023
·
Simone Rossi
, Francesco Gelsomino
, et al.
·
Journal of Neurology
·
70
PDF
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
2020
·
Giuseppe Lamberti
, Monia Sisi
, et al.
·
Cancers
·
69
PDF
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
2022
·
Alessio Cortellini
, Biagio Ricciuti
, et al.
·
Journal for ImmunoTherapy of Cancer
·
41
PDF
Antibody–drug conjugates for lung cancer in the era of personalized oncology
2019
·
Biagio Ricciuti
, Giuseppe Lamberti
, et al.
·
Seminars in Cancer Biology
·
38
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
2023
·
Arianna Zappi
, Irene Persano
, et al.
·
Journal of Clinical Medicine
·
37
PDF
Targeting DNA Damage Response and Repair Genes to Enhance Anticancer Immunotherapy: Rationale and Clinical Implication
2020
·
Giuseppe Lamberti
, Elisa Andrini
, et al.
·
Future Oncology
·
36
An Update on Appendiceal Neuroendocrine Tumors
2023
·
Elisa Andrini
, Giuseppe Lamberti
, et al.
·
Current Treatment Options in Oncology
·
28
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors
2023
·
Nicole Brighi
, Giuseppe Lamberti
, et al.
·
Current Oncology
·
24
Classic versus innovative strategies for immuno-therapy in pancreatic cancer
2025
·
Maria Giovanna Formelli
, Andrea Palloni
, et al.
·
Advanced Drug Delivery Reviews
·
20
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups
2022
·
Fabiana Perrone
, Giulia Mazzaschi
, et al.
·
Cancers
·
19
PDF
Non-small-cell lung cancer: how to manage RET-positive disease
2022
·
Elisa Andrini
, Mirta Mosca
, et al.
·
Drugs in Context
·
18
PDF
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
2022
·
Biagio Ricciuti
, Alessia Mira
, et al.
·
Drugs in Context
·
15
PDF
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
2022
·
Veronica Mollica
, Francesco Massari
, et al.
·
Current Oncology
·
13
PDF
Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
2021
·
Gianluca Ricco
, Elisa Andrini
, et al.
·
International Journal of Molecular Sciences
·
12
PDF
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study
2025
·
Giuseppe Lamberti
, Karim Rihawi
, et al.
·
Journal for ImmunoTherapy of Cancer
·
11
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC
2024
·
Elisa Andrini
, Gianluca Ricco
, et al.
·
Cancer Treatment Reviews
·
11
Endoscopic Ultrasound-Guided Locoregional Treatments for Pancreatic Neuroendocrine Neoplasms
2025
·
Graziella Masciangelo
, Davide Campana
, et al.
·
Current Oncology
·
10
PDF
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature
2023
·
Gianluca Ricco
, Renata Seminerio
, et al.
·
Anti-Cancer Drugs
·
10
A phase II, Open-Label, Single-Arm Trial of Carboplatin Plus Etoposide with Bevacizumab and Atezolizumab in Patients with Extended-Stage Small-Cell Lung Cancer (CeLEBrATE study): Background, Design and Rationale
2022
·
Elisa Andrini
, Giuseppe Lamberti
, et al.
·
Future Oncology
·
10
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
2023
·
Giuseppe Lamberti
, Natalie Prinzi
, et al.
·
Diagnostics
·
9
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort
2024
·
Francesco Panzuto
, Elisa Andrini
, et al.
·
Journal of Clinical Medicine
·
8
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population‐based analysis
2022
·
Giuseppe Lamberti
, Elisa Andrini
, et al.
·
Cancer Medicine
·
7
PDF
Show more works
View as search
Works count:
67
Citation count:
908
H-index:
15
I10-index:
22
Year
Topic
Type